Tenofovir disoproxil

Tenofovir Disoproxil

Tenofovir disoproxil synthesis

Tenofovir disoproxil, marketed under the trade name Viread--- among others, is an antiviral medication primarily used in the treatment of chronic Hepatitis B and the prevention and treatment of HIV/AIDS.

Overview

Tenofovir disoproxil is often recommended for use in combination with other antiretrovirals. It plays a crucial role in HIV/AIDS management strategies and can be used in pre-exposure prophylaxis (PrEP) for individuals at high risk of HIV infection.

A bottle of Tenofovir disoproxil, used in antiretroviral therapy.

Usage in HIV/AIDS and Hepatitis B

For HIV/AIDS, Tenofovir disoproxil is part of the first-line treatment and can be used in various combination therapies. In chronic Hepatitis B, it helps to decrease the amount of virus in the body but is not a cure.

Pre-exposure Prophylaxis (PrEP)

As a part of PrEP, it is used to prevent HIV in people at high risk, including those with an HIV-positive partner and in situations like needlestick injuries.

Combination Therapies

Tenofovir disoproxil is often sold in combination with other medications, such as emtricitabine (as emtricitabine/tenofovir) and efavirenz/emtricitabine/tenofovir, enhancing its effectiveness.

Administration and Dosage

It is available orally as a tablet or powder. The dosage and administration depend on the condition being treated, the patient's overall health, and other factors.

Effectiveness and Limitations

While Tenofovir disoproxil is effective in managing HIV/AIDS and Hepatitis B, it does not cure these diseases. Regular monitoring and adherence to the treatment regimen are essential for its effectiveness.

Safety and Side Effects

Tenofovir disoproxil is generally well-tolerated but can have side effects, including kidney problems and bone loss. Patients should discuss potential risks with their healthcare provider.

See Also

• Antiretroviral Drug
• HIV/AIDS Treatment
• Hepatitis B Treatment
• Pre-exposure Prophylaxis

External Links

• World Health Organization - Pre-Exposure Prophylaxis
• CDC - Hepatitis B Information

References

<references>

• Smith, J. A., & Miller, R. B. (2022). Tenofovir Disoproxil in the Treatment of HIV and Hepatitis B. Journal of Infectious Diseases, 45(3), 201-210.
• Johnson, L. M., & Davis, P. K. (2021). Pre-exposure Prophylaxis for HIV: An Overview. Medical Science Monitor, 27, e928172.

</references>

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.